Activities of daily living in patients with dementia - Clinical relevance, methods of assessment and effects of treatment

被引:160
作者
Desai, AK [1 ]
Grossberg, GT [1 ]
Sheth, DN [1 ]
机构
[1] St Louis Univ, Sch Med, Div Geriatr Psychiat, St Louis, MO 63110 USA
关键词
D O I
10.2165/00023210-200418130-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other than dementia, such as comorbid medical and psychiatric illnesses and sensory impairment. ADL consists of instrumental ADL (IADL) [complex higher order skills, such as managing finances] and basic ADL (BADL) [self-maintenance skills, such as bathing]. Assessment of IADL and BADL is recommended to establish a diagnosis of dementia. Functional assessment also helps the healthcare provider to offer appropriate counselling regarding safety concerns and need for custodial care. Functional capacity measures have been used increasingly in pharmacological trials of patients with Alzheimer's disease (AD) and related dementias, although at the present time these measures are generally not primary outcome measures. Functional impairment is not a uniform construct; rather, it is multifaceted and can be measured with various clinical instruments. Many scales have been validated for use in patients with AD for characterising functional impairment and evaluating the efficacy of treatment. Research to date indicates that cholinesterase inhibitors have the potential for modest but meaningful beneficial effects on ADL in patients with mild-to-moderate AD. Memantine also has promising beneficial effects on functional abilities in persons with moderate-to-severe AD. Assessment of ADL as a primary efficacy measure using a validated scale that is non-gender biased and cross-nationally relevant is recommended in new treatment trials of patients with AD and related dementias.
引用
收藏
页码:853 / 875
页数:23
相关论文
共 131 条
[21]   The effects of donepezil in Alzheimer's disease -: Results from a multinational trial [J].
Burns, A ;
Rossor, M ;
Hecker, J ;
Gauthier, S ;
Petit, H ;
Möller, HJ ;
Rogers, SL ;
Friedhoff, LT .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) :237-244
[22]  
Byrne LMT, 2000, INT J GERIATR PSYCH, V15, P656
[23]   DOCUMENTATION AND EVALUATION OF COGNITIVE IMPAIRMENT IN ELDERLY PRIMARY-CARE PATIENTS [J].
CALLAHAN, CM ;
HENDRIE, HC ;
TIERNEY, WM .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (06) :422-429
[24]   THE PERSPECTIVE OF THE PATIENT WITH ALZHEIMERS-DISEASE - A NEGLECTED DIMENSION OF DEMENTIA RESEARCH [J].
COTRELL, V ;
SCHULZ, R .
GERONTOLOGIST, 1993, 33 (02) :205-211
[25]   Correspondence of the Functional Independence Measure (FIM) self-care subscale with real-time observations of dementia patients' ADL performance in the home [J].
Cotter, EM ;
Burgio, LD ;
Stevens, AB ;
Roth, DL ;
Gitlin, LN .
CLINICAL REHABILITATION, 2002, 16 (01) :36-45
[26]  
*CPMP, 1992, ANT MED PROD
[27]   Use of cholinesterase inhibitors in clinical practice - Evidence-based recommendations [J].
Cummings, JL .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 11 (02) :131-145
[28]   Predicting conversion to Alzheimer disease using standardized clinical information [J].
Daly, E ;
Zaitchik, D ;
Copeland, M ;
Schmahmann, J ;
Gunther, J ;
Albert, M .
ARCHIVES OF NEUROLOGY, 2000, 57 (05) :675-680
[29]  
DEJONG R, 1989, CLIN THER, V11, P545
[30]   Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales [J].
Demers, L ;
Oremus, M ;
Perrault, A ;
Champoux, N ;
Wolfson, C .
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2000, 13 (04) :170-180